ProKidney Corp. (PROK)

NCM – Real Time Price. Currency in USD

1.78

+0.01 (0.56%)

At close: May 12, 2026, 4:00 PM EDT

1.79

+0.01 (0.42%)

After-hours: May 12, 2026, 7:58 PM EDT

25.03.2026

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer.

31.01.2026

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point.

14.01.2026

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

06.01.2026

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.

10.11.2025

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2025, and provided regulatory and clinical updates.

06.11.2025

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with advanced CKD and diabetes. The data, featured in a late-breaking clinical trials presentation at the American Society of Nephrology (ASN) Kidney Week 2025, further demonstrate the potential of rilparencel to preserve kidney function in patients with advanced CKD and diabetes who are at high risk of kidney failure and have limited therapeutic options.

29.10.2025

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in November:

Videos

No Data

There is no data to display

Press releases

25.03.2026

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

10.11.2025

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

06.11.2025

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

20.10.2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX.

ProKidney Corp. (PROK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ProKidney Corp. (PROK)

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

Videos

No Data

Press releases

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

Videos

No Data

Press releases

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025

Search stocks

ProKidney Corp. (PROK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ProKidney Corp. (PROK)

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

Videos

No Data

Press releases

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

Videos

No Data

Press releases

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025